<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00604838</url>
  </required_header>
  <id_info>
    <org_study_id>AlSense-Pivot101</org_study_id>
    <nct_id>NCT00604838</nct_id>
  </id_info>
  <brief_title>Pivotal Study of the Al-Sense Study Protocol</brief_title>
  <official_title>Pivotal Study of the Al-ASense Study Protocol</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Western Galilee Hospital-Nahariya</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Western Galilee Hospital-Nahariya</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to demonstrate that the Diagnostic Absorbent Panty liner
      (AL-SENSE Amniotic Leak Test Kit), developed by Common Sense Ltd., can distinguish between
      wetness sensed by pregnant women that is caused by amniotic fluid leakage and that which is
      caused by urinary incontinence.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">November 2006</completion_date>
  <primary_completion_date type="Actual">November 2006</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>presence or absence of a blue-green stain on a yellow background as yielded by the AL-SENSE and observed by the patient.</measure>
    <time_frame>up to 12 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>presence or absence of a blue-green stain on a yellow background as yielded by the AL-SENSE and observed by the clinician and a measurement of patient comfort while using AL-SENSE and reading the results.</measure>
    <time_frame>up to 12 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">330</enrollment>
  <condition>Amniotic Fluid Leakage</condition>
  <arm_group>
    <arm_group_label>I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AL-SENSE Diagnostic Absorbent Panty liner</intervention_name>
    <description>worn for 12 hours</description>
    <arm_group_label>I</arm_group_label>
    <other_name>AL-SENSE Amniotic Leak Test Kit</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AL-SENSE Diagnostic Absorbent Panty liner</intervention_name>
    <description>Diagnostic Absorbent Panty liner (AL-SENSE Amniotic Leak Test Kit), developed by Common Sense Ltd worn for 12 hours</description>
    <arm_group_label>I</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  age 18 to 45 years.

          -  minimum 16 weeks of pregnancy.

          -  willing to sign the informed consent form.

          -  arrived at the obstetric department reporting a feeling of vaginal wetness
             (undetermined whether this is amniotic fluid leakage or urinary incontinence).

        Exclusion Criteria:

          -  experienced intermittent vaginal bleeding between the 2nd and 3rd trimester.

          -  have had sexual relations within the last 12 hours.

          -  unable or unwilling to cooperate with study procedures.

          -  used the AL-SENSE before joining this study.

          -  diagnosed with Bacterial Vaginosis or Trichomonas infection within the last 3 days.

          -  uses vaginal products such as some douching formulas, some antibiotic treatments which
             reduce lactobacillus population.

          -  uses drugs which reduce estrogen level such as tamoxifen or drugs that dry out the
             mucous membranes, such as antihistamines

          -  on a diet of alkalizing foods such as Alkaliveâ„¢ Green, which may cause elevation of
             the vaginal pH level.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacob Bornstein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Western Galilee Hospital-Nahariya</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yoram Sorokin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wayne State University / Hutzel Women's Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Wayne State University / Hutzel Women's Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Western Galilee Hospital-Nahariya</name>
      <address>
        <city>Nahariya</city>
        <zip>22100</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Watanabe T, Minakami H, Itoi H, Sato I, Sakata Y, Tamada T. Evaluation of latex agglutination test for alpha-fetoprotein in diagnosing rupture of fetal membranes. Gynecol Obstet Invest. 1995;39(1):15-8.</citation>
    <PMID>7534254</PMID>
  </reference>
  <reference>
    <citation>Garite TJ, Gocke SE. Diagnosis of preterm rupture of membranes: is testing for alpha-fetoprotein better than ferning or nitrazine? Am J Perinatol. 1990 Jul;7(3):276-8.</citation>
    <PMID>1695510</PMID>
  </reference>
  <reference>
    <citation>Kishida T, Yamada H, Negishi H, Sagawa T, Makinoda S, Fujimoto S. Diagnosis of preterm premature rupture of the membranes using a newly developed AFP monoclonal antibody test kit. Eur J Obstet Gynecol Reprod Biol. 1995 Jan;58(1):67-72.</citation>
    <PMID>7538939</PMID>
  </reference>
  <reference>
    <citation>Rochelson BL, Rodke G, White R, Bracero L, Baker DA. A rapid colorimetric AFP monoclonal antibody test for the diagnosis of preterm rupture of the membranes. Obstet Gynecol. 1987 Feb;69(2):163-6.</citation>
    <PMID>2433650</PMID>
  </reference>
  <verification_date>January 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 17, 2008</study_first_submitted>
  <study_first_submitted_qc>January 29, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 30, 2008</study_first_posted>
  <last_update_submitted>January 29, 2008</last_update_submitted>
  <last_update_submitted_qc>January 29, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 30, 2008</last_update_posted>
  <responsible_party>
    <name_title>Clinical studies manager</name_title>
    <organization>Common Sense Ltd.</organization>
  </responsible_party>
  <keyword>amniotic fluid leakage</keyword>
  <keyword>urinary incontinence</keyword>
  <keyword>pregnancy</keyword>
  <keyword>home test</keyword>
  <keyword>vaginal wetness</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

